PURPOSE: To evaluate the role of microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agentdocetaxel or doxorubicin chemotherapy. EXPERIMENTAL DESIGN: The analysis was done on 173 tumor samples from patients with locally advanced or metastatic breast cancer who have participated in the TAX-303 phase III trial in which patients were randomly assigned to receive docetaxel or doxorubicin. Expression of total alpha- and beta-tubulin, classes II to IV beta-tubulin isotypes, and tau protein was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded tumors from the primary breast cancer. RESULTS: We observed that patients with "high" expression of class III beta-tubulin isotype had a higher probability of response to docetaxel than to doxorubicin treatment (odds ratio, 1.9; 95% confidence interval, 1.01-3.7; P = 0.05). No difference was observed in terms of time to progression or in terms of overall survival. CONCLUSIONS: This study suggests that the superiority of docetaxel over doxorubicin seems to be confined to the subgroup of patients with "high" expression of class III beta-tubulin isotype.
RCT Entities:
PURPOSE: To evaluate the role of microtubule-associated variables as potential predictors of response and clinical outcome in patients with advanced breast cancer receiving single-agent docetaxel or doxorubicin chemotherapy. EXPERIMENTAL DESIGN: The analysis was done on 173 tumor samples from patients with locally advanced or metastatic breast cancer who have participated in the TAX-303 phase III trial in which patients were randomly assigned to receive docetaxel or doxorubicin. Expression of total alpha- and beta-tubulin, classes II to IV beta-tubulin isotypes, and tau protein was evaluated by immunohistochemistry on formalin-fixed, paraffin-embedded tumors from the primary breast cancer. RESULTS: We observed that patients with "high" expression of class III beta-tubulin isotype had a higher probability of response to docetaxel than to doxorubicin treatment (odds ratio, 1.9; 95% confidence interval, 1.01-3.7; P = 0.05). No difference was observed in terms of time to progression or in terms of overall survival. CONCLUSIONS: This study suggests that the superiority of docetaxel over doxorubicin seems to be confined to the subgroup of patients with "high" expression of class III beta-tubulin isotype.
Authors: R M Hartley; J Peng; G A Fest; S Dakshanamurthy; D E Frantz; M L Brown; S L Mooberry Journal: Mol Pharmacol Date: 2011-12-14 Impact factor: 4.436
Authors: Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs Journal: Mol Cancer Ther Date: 2017-06-14 Impact factor: 6.261
Authors: Lajos Pusztai; Jong-Hyeon Jeong; Yun Gong; Jeffrey S Ross; Chungyeul Kim; Soonmyung Paik; Roman Rouzier; Fabrice Andre; Gabriel N Hortobagyi; Norman Wolmark; W Fraser Symmans Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Lee-Chuan C Yeh; Asok Banerjee; Veena Prasad; Jack A Tuszynski; Alexander L Weis; Tamas Bakos; I-Tien Yeh; Richard F Ludueña; John C Lee Journal: Invest New Drugs Date: 2015-12-21 Impact factor: 3.850
Authors: G Metro; Z Zheng; A Fabi; M Schell; B Antoniani; M Mottolese; A N Monteiro; P Vici; S Lara Rivera; D Boulware; F Cognetti; G Bepler Journal: Cancer Invest Date: 2010-02 Impact factor: 2.176
Authors: Yihong Wang; Joseph A Sparano; Susan Fineberg; Lesley Stead; Jaya Sunkara; Susan Band Horwitz; Hayley M McDaid Journal: Clin Breast Cancer Date: 2012-12-06 Impact factor: 3.225
Authors: S Terry; G Ploussard; Y Allory; N Nicolaiew; F Boissière-Michot; P Maillé; L Kheuang; E Coppolani; A Ali; F Bibeau; S Culine; R Buttyan; A de la Taille; F Vacherot Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640